Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Table 1
Data summary of the participants stratified by AMD phenotype.
PCV
tAMD
total
value
()
()
()
Right eyes (%)
15 (47%)
12 (43%)
27 (45%)
.96†
Males (%)
25 (78%)
23 (82%)
48 (80%)
.95†
Mean age (±SD)Years
74.6 (±9.0)
74.4 (±9.2)
74.5 (±9.0)
.93*
Baseline BCVA LogMAR (±SD)
0.46 (±0.31)
0.64 (±0.39)
0.55 (±0.36)
.053*
Baseline CRT (±SD) μm
414 (±191)
374 (±109)
395 (±158)
.34*
Baseline GLD (±SD) μm
4558 (±1712)
3530 (±996)
4138 (±1479)
.0068*
Subretinal hemorrhage (>1 disc)
9 (28%)
5 (18%)
14 (23%)
.34†
BMI
22.2 (±2.5)
21.2 (±2.5)
22.4 (±2.9)
.56*
Present or ever smoker
20 (63%)
21 (75%)
41 (68%)
.45†
Hypertension
14 (44%)
10 (36%)
24 (40%)
.71†
Diabetes mellitus
5 (16%)
6 (21%)
11 (18%)
.81†
GLD: greatest linear dimension, BCVA: best-corrected visual acuity, CRT: central retinal thickness, and BMI: body mass index. *Unpaired t-test; †×2 test.
